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Twin-to-twin transfusion syndrome is a severe complication occurring in 10% of monochorionic twin pregnancies. The disease is
usually explained as due to an intrauterine imbalance in intertwin blood exchange, which leads to a volume depleted-donor twin
and an overﬁlled recipient twin. The recipient has signs of cardiac dysfunction, which can be measured using echocardiography
or blood and amniotic ﬂuid derived biomarkers. Whereas cardiac dysfunction typically progresses in pregnancies treated with
amniodrainage,itusuallydisappearswithinafewweeksafterfetoscopiclasercoagulationoftheconnectingintertwinanastomoses.
Nevertheless, recipients remain at a increased risk of pulmonary stenosis. In this paper, we summarize the cardiac alterations in
twin-to-twin transfusion syndrome, describe the changes seen after fetal therapy, list the newly proposed staging systems based
on fetal cardiac function, and make recommendations about the use of fetal echocardiography in the evaluation and followup of
pregnancies complicated by twin-to-twin transfusion syndrome.
1.Introduction
Monochorionic diamniotic twin pregnancies carry a 9%–
15% risk of developing twin-to-twin transfusion syndrome
(TTTS) [1, 2]. The pathophysiology of this disease is not
fully understood, but the presence of vascular anastomoses
connecting both fetal circulations at the level of the placenta
is mandatory for its development. In carefully performed
vascular injection studies, anastomoses have been docu-
mented in up to 95% of monochorionic placentas [3, 4],
yet most of these pregnancies remain uncomplicated as the
intertwin blood exchange is in balance. In a small subgroup
however, the distribution of unidirectional arterial to venous
anastomoses is imbalanced and an insuﬃcient number of
compensating bidirectional venovenous or arterio-arterial
anastomoses is present, leading to a net shift of blood from
one twin to the other [5, 6]. The pathophysiology and
therapy of twin-to-twin transfusion syndrome have recently
been covered in an extensive review [7]. In brief, our current
concept is that a net intertwin transfusion takes place over
placentalanastomoses,leadingtovolumeshiftsforwhichthe
fetuses cannot compensate. Additionally, plasma exchange
and hormonal factors may play an important role in the
disease. This ultimately results in a volume depleted donor
twin, who will show signs of oligouria and oligohydramnios
and a volume overloaded recipient twin who will present
with polyuria and polyhydramnios. The diagnosis of TTTS
is based on strict sonographic criteria reﬂecting severe
intertwin ﬂuid discordance. The criteria for TTTS are met
when the deepest vertical amniotic ﬂuid pocket is 2cm or
less in the donors amniotic sac. In Europe, gestational age-
dependent criteria are used to deﬁne the polyhydramnios in
the recipient twin (a deepest amniotic ﬂuid pocket of more
than 8cm prior to 20 weeks and more than 10cm after 20
weeks), whereas in the United States the 8cm cutoﬀ is used
throughout gestation. The disease is currently staged based
on the “Quintero system” which takes in account the ﬁlling
of the bladder in the donor (stage I if the bladder is seen
on ultrasound, stage II if not), the presence of arterial or
venous Doppler ﬂow abnormalities (stage III), the presence
of fetal hydrops (stage IV) and intrauterine fetal demise
(stage V) [8]. When left untreated, TTTS has a mortality2 International Journal of Pediatrics
and morbidity of up to 90%, mainly due to preterm rupture
of the membranes and miscarriage or severe preterm birth
as a result of the massive polyhydramnios [9]. However,
intrauterine demise of one or both fetuses due to severe
cardiac failure can also occur [10]. Treatment of severe
midtrimester TTTS has shifted over the last 10 years from
(repetitive) amniodrainage to fetoscopic laser coagulation of
theconnectingplacentalvessels.Thelattertherapyinterrupts
the intertwin transfusion and has been shown to improve
neonatal survival and to decrease infant morbidity when
compared to amniodrainage in a randomized trial [11, 12].
Although diﬀerent research groups have focused on
this disease and the number of publications on TTTS has
risen exponentially over the last years, we still do not
understand the exact nature of the disease [7]. Consequently,
the currently used staging system does not describe the
naturalevolutionofthedisease,nordoesitpredictindividual
fetal survival after laser surgery adequately. Other insuﬃ-
ciently answered clinical questions are the prediction of the
disease [13–16] and the optimal therapy for early (stage
I) disease (expectant management, amniodrainage, laser)
[17].
In an attempt to address the above questions, and with
the advent of more sophisticated imaging tools in fetal car-
diology [18], fetal medicine specialists and cardiologists have
turnedtocomprehensiveexaminationoftherecipientsheart.
Indeed, one could expect volume shifts towards the recipient
to be reﬂected in progressive cardiac failure. Consequently,
a staging system based on the recipients cardiac function
would make sense from a pathophysiological point of view
and cardiac function assessment could theoretically be used
for predicting the disease and for predicting recipient fetus
survival after laser therapy.
This paper will update the reader on the fetal cardiac
ﬁndings in TTTS and will discuss the indications of fetal
echocardiography in TTTS.
2.EchocardiographicFindingsinTTTS
2.1.RecipientFetuses. Upto70%ofrecipientfetusesofTTTS
show some echocardiographic sign of cardiac compromise
at the time of diagnosis [19], either at the anatomical or
at the functional level. As such, in about half the cases, the
heart is enlarged [20–22] due to an increased myocardial
thickness [23] rather than to ventricular dilatation [10,
24]. In terms of systolic function, shortening fraction is
considerably decreased in 30% of the recipients [10, 21, 22],
and this predominantly at the level of the right ventricle
[10].Accordingly,speckle-tracking-derivedmeasurementsof
strain and strain rate, although diﬃcult to perform, show
decreased strain in the right ventricle of recipient fetuses
of TTTS [25]. In contrast to the lower contractility and to
earlierreportsthatdidnotshowdiﬀerencesincardiacoutput
between donors and recipients [22, 26], two recent series
in relatively large cohorts of recipient fetuses have shown a
moderate increase in cardiac output when corrections were
madeforfetalweight[23,27].Thisﬁndingclearlyﬁtsinwith
the volume overload theory.
In TTTS, diastolic function is even more compromised
than systolic function. As a consequence of the thickened,
dysfunctional myocardium, monophasic ventricular ﬁlling
patterns such as those seen in restrictive cardiomyopathy
occur in about 20%–30% of cases, again with a predom-
inance on the right side [21, 28]. Moreover, we often
observe a shortening of the ventricular ﬁlling time [29],
a prolongation of the isovolumetric relaxation time [30]
and an increase in the Tei-index (which is a geometry
independent indicator of both systolic and diastolic function
based on the assessment of the isovolumetric relaxation and
the isovolumetric contraction time [31, 32]). On average,
the Tei-index is 40% higher than normal [23, 30, 33]a n d
values above the upper limit of normal are observed in
about 50% of cases [24, 28, 30]. Interpretation of the Tei-
index in the fetal setting nevertheless deserves particular
caution as fetal blood pressure is often unknown and
prolongation of the isovolumetric contraction time can be a
reﬂectionofhypertensionratherthanofsystolicdysfunction.
Therefore, separate analysis of the isovolumetric contraction
and relaxation time is justiﬁed, yet only technically possible
at the level of the left ventricle due to the implantation of
the pulmonary and tricuspid valve precluding simultaneous
recording of the pulmonary and tricuspid ﬂow.
Tricuspid regurgitation occurs in about 30%–50% of
recipients [21, 28, 34] but is severe in only half of these
[10, 21–23]. Mitral regurgitation on the other hand is much
less frequent (6%–14% of cases) [21, 28], yet usually severe
(9%) [21]. The presence of valvular regurgitation allows to
estimate fetal blood pressure using the Bernouilli equation
and studies have shown that recipient fetuses display marked
hypertension with systolic pressures over 2-fold the normal
value for gestational age [35].
Further down the vascular tree, Doppler assessment of
the ductus venosus and the umbilical venous ﬂow allows
to estimate the right atrial pressure curve. Reversed ﬂow in
the ductus venosus and umbilical vein pulsations have been
integrated in the Quintero staging system and their presence
upstages the disease to stage III. In most series from tertiary
referral centers, abnormal ductus venosus dopplers are seen
in about 1 in 3 recipients [21, 23, 28, 34] and a pulsatile
umbilical vein in 1 in 10 [21, 22, 28].
A summary of the fetal echo ﬁndings in a prospective
series of 78 consecutive cases seen in our unit is presented
in Table 1 (unpublished data). It is important to note that
in Quintero stage I, already 45% of cases show signs of
ventricular dysfunction in terms of an increased Tei index
and that 35% of cases have a fused right ventricular inﬂow
pattern suggestive of diastolic dysfunction. The occurrence
of these so-called early ﬁndings remains relatively stable over
stage I to III, similar to what has been published earlier [24].
Nevertheless, other ﬁndings such as the left ventricular
Tei-index and mitral and tricuspid regurgitation increase
withQuinterostage[21]suggestingthattheQuinterostaging
system, at least to some degree, reﬂects progressive fetal
cardiovascular compromise.
Our group has shown that changes in cardiac function
are already present well before the actual development of
TTTS.Assuch,about30%offetuseswithmoderateamnioticInternational Journal of Pediatrics 3
Table 1: Occurence of cardiac function alterations in 78 consecutive recipient fetuses assessed at the University Hospitals Leuven, Belgium.
Stage I (n = 11) Stage II (n = 19) Stage III (n = 42) Stage IV (n = 6) Overall (n = 78)
Reversed a-wave ductus
venosus (%) 006 2 5 0 3 7
Umbilical vein pulsations (%) 0 0 50 67 32
Fusion of RV inﬂow (%) 36 37 38 83 41
Tricuspid regurgitation (%) 9 21 38 67 31
RV-MPI > percentile
97.5 (%) 45 47 48 83 49
Fusion of LV inﬂow (%) 9 21 29 67 27
Mitral regurgitation (%) 0 0 10 50 10
LV-MPI > percentile
97.5 (%) 25 42 38 83 41
RV: right ventricle, LV: left ventricle, and MPI: myocardial performance index.
ﬂuid discordance not fulﬁlling the criteria of TTTS but
ultimately progressing to the syndrome show an increased
myocardial performance index [36]. Along the same line,
40% of monochorionic twins that ultimately will develop
TTTS have already abnormal ﬁndings in the ductus venosus
ﬂow[1,13]ordiscordantnuchaltranslucencymeasurements
reﬂective of altered hemodynamics in the ﬁrst trimester of
pregnancy [14, 15, 37]. Unfortunately, these ﬁndings are not
very speciﬁc, nor very sensitive. They cannot therefore be
used for early prediction of the disease, nor should they be
used to “upstage” (often benign) ﬂuid discordance to TTTS.
Once a TTTS is fully installed, echocardiographic ﬁnd-
ings tend to progress over time, with worsening ventricular
hypertrophy and systolic dysfunction, which can ultimately
lead to fetal hydrops and intrauterine fetal demise [38].
M o r e o v e r ,a sg r o w t ho ff e t a lc a r d i a cs t r u c t u r e si sd e p e n d e n t
on the blood ﬂow through them, persistent ventricular
dysfunction can lead to secondary anatomic changes. Con-
sequently, in a consecutive series of 150 recipient fetuses,
16% had a smaller than expected right ventricular outﬂow
tract at the time of initial presentation [21]. In up to 4%,
extremerightventriculardysfunctioncanresultinfunctional
pulmonary atresia (Figure 1) with retrograde perfusion of
the pulmonary trunk through the ductus arteriosus [10, 34]
and more rarely even in complete right heart ﬂow reversal
[39].
2.2. Donor Fetuses. In contrast to recipient fetuses, donors
seem to have a normal cardiac function, yet some 5%–10%
p r e s e n tw i t ha b n o r m a lD o p p l e rw a v e f o r m si nt h ed u c t u s
venosus, and 3% with tricuspid regurgitation or umbili-
cal vein pulsations [34, 40], ﬁndings which are generally
explained by the presence of severe placental insuﬃciency.
The latter is also supported by an increased occurrence of
abnormal diastolic ﬂow in the umbilical artery in the donor
fetus.
Furthermore, although not signiﬁcant in most studies,
the donor twin has a trend towards a lower Tei-index than
in the normal population which is suggestive of hypotension
[27, 40]. Finally, there have been speculations about an
increased incidence of aortic coarctation in donors due to a
lower venous return from the placenta and hence a decreased
loading of the left ventricular outﬂow tract [41].
3. Biomarkers of Altered Fetal
Hemodynamics inTTTS
DiﬀerentvasoactivepeptideshavebeeninvestigatedinTTTS,
mainly in an attempt to further explain the underlying
pathophysiological mechanisms.
Thereninangiotensinaldosteronesystemhasbeenfound
to be upregulated in the donor kidney [42]. Transfer of
these hormones towards the recipient through the placental
anastomoses partly explains the hypertension (angiotensin
II) and the hypervolemia (aldosterone) seen in this fetus.
Additional upregulation of atrial natriuretic factor (ANF)
has been observed in recipients when compared to donor
fetuses [43]. Plasma levels of ANF are correlated with the
amount of amniotic ﬂuid yet not with the severity of cardiac
dysfunction [43] and are therefore thought to mediate the
recipients polyuria.
Increased endothelin-1 [44], brain or b-type natriuretic
peptide (BNP) [28, 44, 45] and cardiac troponin T [28]
levels have been observed in the plasma and/or the amniotic
ﬂuid of recipient fetuses, similar to observations in adults
with chronic heart failure. Endothelin-1 can certainly play
a role in the development of the severe hypertension [35,
44], stimulates the myocardial remodeling [46]a n dc o u l d
decrease cardiac function. The presence of both BNP and
cardiac troponin T [28] suggests that the myocardium is not
only stretched by the volume load but also that it undergoes
structural damage/remodeling.
4. New StagingSystemsinTTTS
In an attempt to provide a more pathophysiologic classiﬁ-
cation of TTTS [47], diﬀerent groups have suggested to use
new staging systems that are mainly based on the severity of
cardiacdysfunctionintherecipientfetus.Themostextensive
system has been elaborated by the Children’s Hospital Of
Philadelphia (CHOP) [21] and requires the evaluation of 124 International Journal of Pediatrics
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Figure 1: Common echocardiographic ﬁndings in the recipient of TTTS. (a) Reversed ﬂow in the ductus venosus. (b) Umbilical vein
pulsations. (c) Transverse view of the fetal chest at the level of the 3-vessel view demonstrating forward ﬂow in the aorta (blue) and reversed
ﬂow in the ductus arteriosus and pulmonary artery (red) suggestive of functional pulmonary atresia. (d) Doppler assessment at the level of
the fetal 4-chamber view demonstrating mitral and tricuspid regurgitation with the corresponding pulsed Doppler spectrum below.
variables which, in experienced hands, takes 30–45 minutes
per fetus and is therefore not feasible in routine clinical
practice (Table 2). Also, diﬀerent parameters of cardiac
function are correlated. For example, we have shown that the
ejection fraction correlates with the myocardial performance
index [33] and others demonstrated that abnormal ﬂow in
the ductus venosus correlates with tricuspid regurgitation
[34]. Finally, Rychik et al. [21] showed that the right
ventricular Tei-index was strongly correlated with their full
12 parameter score, suggesting that the creation of an easier
staging system, still encompassing the full extent of the
disease should be feasible.
Going further into this, Stirnemann et al. [23] used
cluster analysis and partitioning algorithms to determine
that a staging system including only the assessment of the
left and right ventricular myocardial performance index
allows to stratify cases as well as a system with additional
inclusion of shortening fractions, ductus venosus pulsatility
index and cardiac output. A comparison of the anatomic and
functional parameters in the diﬀerent proposed “cardiac”
staging systems is presented in Table 2.
At present, we do not feel that these new staging
systems should replace the Quintero system, which is an
easy and widely accepted method for patient stratiﬁcation
that has proven some usefulness in terms of predicting fetal
outcome after laser therapy [11, 49]. Nevertheless, cardiac
staging systems may play an important role in the further
understanding of the pathophysiology of the disease and are
useful in research settings.
5. Effect of PrenatalTherapy
Amniodrainage usually does not cure TTTS but is rather a
palliative and repetitive intervention aimed at relieving the
polyhydramnios. As such, it does not improve fetal cardiac
function and fetuses undergoing repetitive amniodrainage
show progressive cardiac disease and hydrops and are at risk
for intrauterine demise [10, 50].
On the other hand, closure of the vascular anastomoses
at the level of the placenta and functional separation of
both fetuses by fetoscopic laser leads to a rapid improvement
in cardiac function in the recipient fetus. Already in the
ﬁrst 48 hours after therapy, cardiac size, precordial venous
Dopplers, valvular regurgitation, and ventricular inﬂow
patterns normalize in about half of the cases and the
Tei-index improves with approximately 40% [19, 20, 40,
51]. Survival is worse in fetuses lacking this functional
improvement immediately after surgery [19]. In the longer
term, further amelioration in cardiac function continues
and approximately 6 weeks after therapy most cases have
regained normal cardiac function [40]. The normalization
of cardiac dysfunction is very similar to, but slightly faster
than, what is seen in neonates delivered at the time of TTTSInternational Journal of Pediatrics 5
Table 2: Comparison of the cardiac parameters assessed in the diﬀerent proposed staging systems.
Quintero et al. 1999 [8] Rychik et al. 2007 [21] Shah et al. 2008 [48] Habli et al. 2008 [19] Stirnemann et al.
2010 [23]
“CHOP-score” “Cardiovascular
proﬁle score” “Cincinatti staging”
Cardiothoracic ratio x x
Ventricular wall thickness x x
Shortening fraction x x
Tei-index right ventricle x x
Tei-index left ventricle xx
AV regurgitation x x x
AV inﬂow x
Pulmonary insuﬃciency x
Outﬂow tract size x
Ductus venosus x x x x
Umbilical vein x x x x
Hydrops x x x
Umbilical artery donor x x x x
AV: ventricular valve.
[52]. Interestingly, even severe cardiac dysfunction such as
functional pulmonary atresia and hydrops resolve in almost
all cases [51, 53], which argues against the use of selective
reduction in these fetuses.
In contrast to recipients, about 1 in 4 donor fetuses has
a temporary worsening in cardiac function with increased
cardiac size [20], tricuspid regurgitation, ductus venosus
alterations, and subcutaneous oedema [34, 40, 54]a f t e rf e t o -
scopic laser therapy. These ﬁndings however disappear by 2–
4 weeks after the surgery [40, 54] and are probably explained
by the sudden arrest of the transfusion imbalance and tem-
porary relative volume overload in the former donor fetus.
Diﬀerent groups have investigated whether fetal demise
after laser therapy (which occurs in about 18% of recipient
fetuses [49]) can be predicted by preoperative fetal cardiac
function. In a retrospective series, Shah and colleagues
showedthatrecipientcardiovascularproﬁlescorecanpredict
outcome to a certain extent [48]. In line with this ﬁnding,
we have shown that recipient fetuses with a normal Tei-
index and low amniotic ﬂuid cardiac troponin T levels have
an improved survival compared to those with alterations
in either of these 2 parameters. However, cardiac function
alonedoesnotpredictoutcome[28],asconﬁrmedinalarger
multicenter series including more than 200 TTTS cases [55].
This is explained by the fact that fetal demise after laser
is multifactorial and also depends on other factors such as
placental sharing or incomplete laser separation. For clinical
practice, it means that for now, fetal therapy cannot be
tailored to the individual situation based on fetal cardiac
function assessment.
6.LongTermCardiacOutcomeafterTTTS
Followupuntiltheageof10yearhasshownthatbothdonors
andrecipientsofnonlaseredTTTShavenormalcardiacfunc-
tion in the longer term [56]. Recipient twins nevertheless
maintain a slightly reduced early diastolic ventricular ﬁlling
as compared to donors (diastolic dysfunction). Donors on
theotherhandseemtohavehigherarterialwallstiﬀnessthan
recipients, suggestive of intrauterine vascular programming
[57]. Fetoscopic laser therapy can alter this prenatal vascular
programming. As such, fetuses that underwent laser have
normal wall stiﬀness and normal cardiac function at the
age of 2 year [58, 59]. However, the increased occurrence of
right ventricular outﬂow tract obstruction observed at the
time of TTTS (16%) [21] does not disappear completely and
recipient fetuses remain at a 3-fold increased risk (5%–8%)
of pulmonary stenosis at the time of birth when compared to
uncomplicated monochorionic twins [22, 59].
7. ClinicalRecommendations
In clinical practice, the main question remains whether
(functional) fetal echocardiography should be used in the
evaluation and follow-up of pregnancies complicated with
TTTS and if the answer is yes, when echocardiography
should be performed. From the above listed data, we feel
that the only clinically useful echocardiographic ﬁnding in
TTTS pregnancies booked for fetoscopic laser therapy is
the presence of persistent pulmonary artery stenosis after
therapy which would impact on the place of delivery and on
postnatal management. As a result, we would recommend a
thorough(structural)cardiacevaluation8–10weeksafterthe
fetoscopic surgery, when cardiac dysfunction has completely
resolved, to assess pulmonary artery development and to
plan the site of delivery.
In TTTS pregnancies managed expectantly or undergo-
ing (repetitive) amniodrainage, the evidence is less clear, yet
we feel they should undergo intensive cardiac follow-up with
at least assessment of ductus venosus and umbilical vein ﬂow6 International Journal of Pediatrics
and evaluation for the presence of hydrops to time eventual
delivery or to switch therapy to laser before intrauterine fetal
demise occurs. Additionally, these fetuses should undergo
evaluation for pulmonary artery stenosis before birth.
As all recipient fetuses of TTTS, both managed conser-
vatively or with laser, are at increased risk of pulmonary
artery stenosis, we are convinced that an early postnatal
screening echocardiogram is indicated. Moreover, because
all monochorionic twins are at increased risk for structural
cardiac abnormalities compared to singletons or dichorionic
twins [22], all should beneﬁt from midtrimester structural
echocardiographic assessment
8. Conclusions andFuturePerspectives
In summary, cardiac dysfunction is a common ﬁnding in
recipient fetuses and diﬀerent new “cardiac” staging systems
have been proposed. Although they may bring new patho-
physiologic insights, their clinical value remains limited as
they do not predict the occurrence nor the outcome of the
disease. However, further evaluation is necessary in stage I
disease, where equipoise is still present about the optimal
treatment strategy [17]. Additionally, the impact of the
decreased cardiac function on cerebral perfusion and long-
term neurologic development requires further investigation.
Fetoscopic laser coagulation of the vascular anastomoses
interrupts the intertwin transfusion and has been shown to
lead to fast normalization of cardiac function. Nevertheless,
recipients remain at increased risk of pulmonary artery
stenosis. Further work should be directed at detecting
prenatally which twins will have clinically important lesions
at the time of birth.
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